Propanc Biopharma Executes Service Agreement with FyoniBio for Pharmacokinetics Assay in Phase 1b First-In-Human Study

Propanc Biopharma has executed a service agreement with FyoniBio to establish and validate a pharmacokinetics assay for its Phase 1b First-In-Human study. The assay will quantify the Company's lead asset, PRP, and its activated enzyme forms in human serum during the study. The LC-MS PK assay aims to measure the systemic concentration of PRP and its analytes over time in advanced cancer patients. Results will evaluate safety, tolerability, and efficacy of PRP in patients. The method development work initiated will support the upcoming study, which is planned to commence in Q4 2026.